The U.S. Food and Drug Administration approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months or longer without another identifiable non-blood related cause of the disease.

The U.S. Food and Drug Administration approved GlaxoSmithKline plc’s Nucala (mepolizumab) for the treatment of adult and pediatric patients aged 12 years and older with Hypereosinophilic Syndrome (HES) for ≥ six months without an identifiable non-hematologic secondary cause.

Two months after winning approval from the U.S. Food and Drug Administration as an asthma treatment, GlaxoSmithKline is eying another potential regulatory win for Nucala following positive Phase III results in the treatment of patients living with hypereosinophilic syndrome (HES).